Clinical Trials Logo

Recurrent Pancreatic Cancer clinical trials

View clinical trials related to Recurrent Pancreatic Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01233505 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and the best dose of veliparib when given together with capecitabine and oxaliplatin in treating patients with advanced solid tumors. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with capecitabine and oxaliplatin may kill more tumor cells.

NCT ID: NCT01227018 Terminated - Clinical trials for Stage IV Pancreatic Cancer

PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer

Start date: December 2010
Phase: Phase 2
Study type: Interventional

RATIONALE: Heat shock protein (HSP)90 inhibitor STA-9090 may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. PURPOSE: This phase II trial is studying how well hsp90 inhibitor STA-9090 works as second- or third-line therapy for the treatment of patients with metastatic pancreatic cancer.

NCT ID: NCT00482625 Terminated - Clinical trials for Stage III Pancreatic Cancer

Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Start date: June 2007
Phase: Phase 2
Study type: Interventional

Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib hydrochloride before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. This phase II trial is studying how well erlotinib hydrochloride works in treating patients with pancreatic cancer that can be removed by surgery

NCT ID: NCT00087191 Terminated - Clinical trials for Fallopian Tube Cancer

EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer

Start date: May 2004
Phase: N/A
Study type: Interventional

This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer. EF5 may be effective in measuring oxygen in tumor tissue. Photosensitizing drugs such as motexafin lutetium are absorbed by tumor cells and, when exposed to light, become active and kill the tumor cells. Knowing the level of oxygen in tumor tissue and the level of motexafin lutetium absorbed by tumors and normal tissue may help predict the effectiveness of anticancer therapy